ProfoundBio

ProfoundBio is now part of Genmab. As part of Genmab, we are looking forward to continuing our work of developing novel antibody-based therapeutics for patients with cancer. This page will no longer be active or monitored. For updates on our work, please follow Genmab.  Read the press release: https://bit.ly/4dQTtSe.

Are you going to be at #AACR2024 in San Diego? Don’t miss ProfoundBio’s presentations from our novel #ADC pipeline. Read more: https://lnkd.in/ga2ffDfq. #cancerresearch #biotech

Excited to share ProfoundBio will be acquired by Genmab—this is a big step in our journey to make a positive impact for patients with #cancer through our novel ADC technology and pipeline.

Proud to share that ProfoundBio has secured $112 million in an oversubscribed Series B round, fueling our mission to advance novel cancer treatments, including advancing our flagship #ADC, rinatabart sesutecan (Rina-S) into late-stage clinical development. Deep gratitude to our esteemed life science investors for backing our vision. A big welcome to Andrew Lam, PharmD, Eric Dobmeier, and Enoch Kariuki, PharmD for joining our Board of Directors. With their guidance, we're diving deep into the next phase of innovation in #cancerresearch Learn more: https://lnkd.in/djG5g9EM #AntibodyDrugConjugates #Oncology #TargetedTherapy #SeriesBFinancing #BiotechInnovation

ProfoundBio is thrilled to announce the initiation of dosing in the Phase 1/2 clinical trial of PRO1107, marking a significant step forward in our efforts to develop antibody-drug conjugates (ADCs) with improved clinical outcomes for cancer patients. PRO1107 is a pioneering Protein Tyrosine Kinase 7 (PTK7)-targeted ADC that leverages our novel, proprietary hydrophilic MMAE-based linker-drug, aiming to set new standards in safety and efficacy for MMAE-based ADCs in the fight against cancer. A heartfelt thank you to our dedicated investigators and the patients participating in this trailblazing research. Your involvement is pivotal in driving forward our mission to deliver groundbreaking treatments. Read more: https://lnkd.in/gKXsEwsB #ProfoundBio #ClinicalTrial #CancerResearch #InnovationInOncology #BiotechLinkedIn

📣 ProfoundBio is thrilled to announce that rinatabart sesutecan (Rina-S) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA)! See our press release for more info 👉 : https://lnkd.in/gx9MUXiJ

📣 We’re excited to announce several additions to the ProfoundBio team, including Erin Lavelle, Kevin Hambly, and Dr. Lori Kunkel, who will support us as we enter our next stage of growth. These leaders join our executive team with deep drug development and ADC expertise across more than a dozen FDA-approved drugs and >15 clinical-stage ADCs.   Read more about this news here: https://lnkd.in/dut5sm8g #ProfoundBio #ADCs #Growth

📣 We’re excited to present initial results from the dose escalation portion of an ongoing Phase 1/2 trial of our folate receptor-alpha (FRα)-directed ADC, rinatabart sesutecan (Rina-S; PRO1184) at SITC 2023: ●     Rina-S demonstrated a high response rate in heavily pre-treated patients with ovarian and endometrial cancers ●     Responses were observed across the full spectrum of FRα expression and at doses that were well-tolerated ●     These data validate our approach to developing ADCs with the potential for meaningfully improved outcomes for patients   We are also pleased to share preclinical data on our Protein Tyrosine Kinase 7 (PTK7)-directed ADC, PRO1107, which is expected to begin enrollment in a Phase 1/2 trial in early 2024.   Learn more about these encouraging data here: https://lnkd.in/dkYSuteD  #ProfoundBio #ADCs #Growth #SITC #SITC23

📣 We’re excited to announce several additions to the ProfoundBio team, including Erin Lavelle, Kevin Hambly, and Dr. Lori Kunkel, who will support us as we enter our next stage of growth. These leaders join our executive team with deep drug development and ADC expertise across more than a dozen FDA-approved drugs and >15 clinical-stage ADCs.   Read more about this news here: https://lnkd.in/dut5sm8g #ProfoundBio #ADCs #Growth

ProfoundBio will be attending multiple investor conferences in November. We look forward to meeting investors at the Wells Fargo 2023 Virtual Private Biotech Symposium on Nov 1, and the Piper Sandler 35th Annual Healthcare Conference Nov 28-30. https://lnkd.in/gvSFZBnm